For: | Placido SD, Rescigno P, Federico P, Buonerba C, Bosso D, Puglia L, Izzo M, Policastro T, Lorenzo GD. Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. World J Clin Cases 2014; 2(6): 228-231 [PMID: 24945013 DOI: 10.12998/wjcc.v2.i6.228] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v2/i6/228.htm |
Number | Citing Articles |
1 |
Giuseppe Di Lorenzo, Sergio Bracarda, Donatello Gasparro, Angela Gernone, Caterina Messina, Vittorina Zagonel, Livio Puglia, Davide Bosso, Davide Dondi, Guru Sonpavde, Giuseppe Lucarelli, Sabino De Placido, Carlo Buonerba. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine 2016; 95(2): e2299 doi: 10.1097/MD.0000000000002299
|
2 |
Sachin Patil, Vishnu S. Mishra, Nisha Yadav, Puli Chandramouli Reddy, Bimlesh Lochab. Dendrimer-Functionalized Nanodiamonds as Safe and Efficient Drug Carriers for Cancer Therapy: Nucleus Penetrating Nanoparticles. ACS Applied Bio Materials 2022; 5(7): 3438 doi: 10.1021/acsabm.2c00373
|
3 |
Quinn T. Ostrom, Christina Huang Wright, Jill S. Barnholtz-Sloan. Metastatic Disease of the Nervous System. Handbook of Clinical Neurology 2018; 149: 27 doi: 10.1016/B978-0-12-811161-1.00002-5
|
4 |
Peter E. Manley, Tanya Trippett, Amy A. Smith, Margaret E. Macy, Sarah E.S. Leary, Jessica Boklan, Kenneth J. Cohen, Stewart Goldman, Lindsay B. Kilburn, Girish Dhall, Jeanne Devin, Cynthia E. Herzog, Sonia Partap, Floris Fauchet, Emmy Badreddine, John P. Bernard, Susan N. Chi. A phase 1/2 dose‐finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood & Cancer 2018; 65(9) doi: 10.1002/pbc.27217
|
5 |
Michael Kolinsky, Niven Mehra, Johann S. de Bono. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. 2016; : 187 doi: 10.1007/978-3-319-31341-2_12
|
6 |
Keitaro Watanabe, Takeo Kosaka, Hiroshi Hongo, Satoshi Tamaki, Mototsugu Oya. Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy. The Keio Journal of Medicine 2017; 66(4): 65 doi: 10.2302/kjm.2016-0014-CR
|
7 |
Atsushi Mizokami, Yoshifumi Kadono, Yasuhide Kitagawa, Kouji Izumi, Hiroyuki Konaka. Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. International Journal of Urology 2017; 24(8): 566 doi: 10.1111/iju.13372
|
8 |
Pallavi Duggal, Kuldeep S. Jadaun, Ehraz M. Siqqiqui, Sidharth Mehan. Investigation of Low Dose Cabazitaxel Potential as Microtubule Stabilizer in Experimental Model of Alzheimer's Disease: Restoring Neuronal Cytoskeleton. Current Alzheimer Research 2020; 17(7): 601 doi: 10.2174/1567205017666201007120112
|
9 |
Carlo Buonerba, Giuseppe Di Lorenzo.
Is
In Vitro
-Acquired Resistance to Enzalutamide a Useful Model?
. Future Oncology 2014; 10(16): 2551 doi: 10.2217/fon.14.212
|
10 |
Martina Pagliuca, Carlo Buonerba, Karim Fizazi, Giuseppe Di Lorenzo. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs 2019; 79(4): 381 doi: 10.1007/s40265-019-1060-5
|
11 |
Giuseppe Di Lorenzo, Carlo Buonerba, Sabino de Placido. Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. Anti-Cancer Drugs 2015; 26(2): 236 doi: 10.1097/CAD.0000000000000180
|
12 |
Begoña Mellado, Natalia Jimenez, Mercedes Marin-Aguilera, Oscar Reig. Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer 2016; 14(4): 265 doi: 10.1016/j.clgc.2015.12.030
|
13 |
Carlo Buonerba, Giuseppe Di Lorenzo, Guru Sonpavde. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. Expert Review of Molecular Diagnostics 2016; 16(10): 1113 doi: 10.1080/14737159.2016.1240031
|
14 |
Yohei Shida, Tomoaki Hakariya, Yasuyoshi Miyata, Hideki Sakai. Three cases of brain metastasis from castration‐resistant prostate cancer. Clinical Case Reports 2020; 8(1): 96 doi: 10.1002/ccr3.2587
|
15 |
Timothy L. Sita, Katarina G. Petras, Q. Eileen Wafford, Mark A. Berendsen, Tim J. Kruser. Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review. Journal of Neuro-Oncology 2017; 133(3): 531 doi: 10.1007/s11060-017-2460-6
|
16 |
Joseph Bteich, Mark J. Ernsting, Mohammed Mohammed, Taira Kiyota, Trevor D. McKee, Mohit Trikha, Henry B. Lowman, Kenneth K. Sokoll. Nanoparticle Formulation Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel for Chemotherapy Delivery to the Brain. Bioconjugate Chemistry 2018; 29(6): 2009 doi: 10.1021/acs.bioconjchem.8b00220
|
17 |
Seyyedmohammadsadeq Mirmoeeni, Amirhossein Azari Jafari, Muffaqam Shah, Fateme Salemi, Seyedeh Zohreh Hashemi, Ali Seifi, Hendrik Van Poppel. The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review. Prostate Cancer 2022; 2022: 1 doi: 10.1155/2022/5324600
|